Zydus Pharma subsidiary gets approval for Oseltamivir capsules in USA
Zydus Pharma subsidiary Nesher Pharmaceuticals has received approval from the USFDA to sell Oseltamivir Phosphate capsules. The medication, an anti-viral used to treat influenza, has an estimated annual sales of $382 million in the US. Flu season in the US typically starts in October and goes on till March, which is the time sales of influenza medication is the highest. Zydus' Nesher Pharmaceuticals receives final approval from the USFDA for Oseltamivir Phosphate Capsules
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 27, 2017 titled "Zydus' Nesher Pharmaceuticals receives final approval from the USFDA for Oseltamivir Phosphate Capsules". Zydus Cadila to launch influenza fighting vaccine in India
The vaccine provides protection from four influenza viruses -- H1N1, H3N2, Type B (Brisbane) Zydus Cadila to launch Indias 1st Tetravalent Inactivated Influenza vaccine - VaxiFlu - 4
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 24, 2017, titled "Zydus Cadila to launch Indias 1st Tetravalent Inactivated Influenza vaccine - VaxiFlu - 4". Tribunal Convened Meeting on March 30, 2017
Cadila Healthcare Ltd has submitted to BSE a copy of notice of Tribunal Convened Meeting of the Equity Shareholders of the Company will be held on March 30, 2017. Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC)
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 23, 2017, titled "Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC)". Investor Presentation
Cadila Healthcare Ltd has informed BSE that the Company is going to participate in IIFL Investor Conference scheduled to be held on February 22, 2017. Fixes Record Date for Interim Dividend
Cadila Healthcare Ltd has informed BSE that the Company has fixed March 17, 2017 as the Record Date for the purpose of Payment of Interim Dividend, if declared.
Cadila Healthcare regains glow as Moraiya gets USFDA green light
Cadila share rose by 25% over two days after its Moraiya facility passed an inspection by the US drug regulator Board to consider Interim Dividend
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on March 07, 2017, to consider, the proposal of declaration of Interim Dividend, if any, for the financial year 2016-2017.Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from February...